Agoracom Blog Home

Posts Tagged ‘CSE’

« Older Entries
Newer Entries »

Empower Clinics $CBDT.ca Announces April 2020 Patient Growth of 871% and Orders Additional Supplies for #Covid19 Testing $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 8:39 AM on Tuesday, May 5th, 2020
  • EMPOWER SEES SUBSTANTIAL YEAR-OVER-YEAR PATIENT GROWTH WHILE ROLLING OUT ADDITIONAL SERVICES AND CONTINUES TO PURCHASE SUPPLIES AND EQUIPMENT TO SUPPORT EXPANSION OF COVID-19 ANTIBODY TESTING
  • Patient visits in corporate clinics increased by 871% in April 2020 versus the same period in 2019,
  • Total patient visits of 2,212 in April 2020 compared to 254 in April 2019.

VANCOUVER, BC / May 5, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated life sciences company, is pleased to announce that patient visits in corporate clinics increased by 871% in April 2020 versus the same period in 2019, with total patient visits of 2,212 in April 2020 compared to 254 in April 2019.

The Company is booking new physician appointments for immune boosting services that are leading to naturopathic product sales and the ordering of specialized tests. In addition, the Company has increased orders of Personal Protective Equipment (PPE) and equipment such as stainless-steel tables, portable air conditioning units, tents and medical supplies to support staff and patients as part of a medical testing protocol in the United States.

The Company has also been identified by Amazon Business as needing access to critical supplies and as such, the Company has been awarded access to the Amazon COVID-19 SUPPLIES portal, which provides access to essential products for organizations participating in the fight against Coronavirus.

“The performance results from April are truly outstanding and given the operational changes the team have made as a result of Coronavirus, I am immensely proud of their efforts” said Steven McAuley, Chairman & CEO of Empower. “We are starting to see strong diversification in the revenue model for our clinics that will help us grow not only patient count, but revenue per patient, total revenue and perhaps more importantly, create revenue diversity to reduce concentration risk for the business model.”

ABOUT EMPOWER

Empower is a vertically integrated health & wellness brand with a network of corporate and franchised health & wellness clinics in the U.S. The Company is building its first hemp-derived CBD extraction facility and produces its proprietary line of cannabidiol (CBD) based products. The Company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company now offers COVID-19 testing options in the United States and physician-based consultations, to address COVID-19 concerns.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley
CEO
[email protected]
604-789-2146

Investors: Dustin Klein
SVP, Business Development
[email protected]
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws.All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s expected timing of filing of its Annual Filings, the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four as noted above, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Tags: , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca Announces April 2020 Patient Growth of 871% and Orders Additional Supplies for #Covid19 Testing $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

#EdTech firm Byju’s could become India’s second most valued startup – SPONSOR: BetterU Education Corp. $BTRU.ca $ARCL $CPLA $BPI $FC.ca

Posted by AGORACOM-JC at 3:28 PM on Monday, May 4th, 2020

SPONSOR:  BetterU Education Corp. aims to provide access to quality education from around the world. The company plans to bridge the prevailing gap in the education and job industry and enhance the lives of its prospective learners by developing an integrated ecosystem. betterU / Ottolearn launch FREE COVID-19 mobile resource toolkit to fight the global crisis – Click here for more information.

EdTech firm Byju’s could become India’s second most valued startup

By Nitesh Kumar

  • Byju’s the Bengaluru-based ed-tech startup  has been through numerous rounds of valuations and this time around it is expected to raise upwards of $400 million in fresh capital at a $10 billion, reports suggest. 

What started off as a penchant for simple, yet effective teaching methods by Byju Raveendran, Founder of Byju’s, could now become India’s second most valued startup, if it manages to raise fresh capital.  

The startup has witnessed a marked increase in the app downloads and learners due to the ongoing nationwide Covid-19 lockdown. It had earlier received an investment from Tiger Global and General Atlantic that stood around $300 million to $350 million and was valued at $8 billion. 

Back in July 2019, Byju’s was valued at $5.75 billion when it raised $150 million from Qatar Investment Authority and Owl Ventures. 

If this fresh round of funding goes through, Byju’s would become the second most valued startup in India along with budget lodging startup Oyo which is also valued at $10 billion.  Paytm, the financial services firm had raised $1 billion at a $16 billion valuation late last year and currently holds the number one spot.

Industry watchers are suggesting that discussions are afoot though nothing has yet been finalised around the terms. Both Byju’s and Prosus Ventures have been silent about the reports that appeared in sections of the Indian media. 

There were reports that last month Byju’s witnessed 150% increase in traffic on its app and website while adding six million students to its platform during the same period.

Byju’s helps school-going kids understand difficult subjects by illustrating them using familiar objects like pizza and cake. Those pursuing undergraduate and graduate-level courses also learn on the platform.

At the moment, the edtech has over 35 million registered learners of which around 2.4 million are paid users.

Source: https://www.techradar.com/in/news/edtech-firm-byjus-could-become-indias-second-most-valued-startup

Tags: , , , , , , ,
Posted in All Recent Posts, betterU Education Corp | Comments Off on #EdTech firm Byju’s could become India’s second most valued startup – SPONSOR: BetterU Education Corp. $BTRU.ca $ARCL $CPLA $BPI $FC.ca

Datametrex $DM.ca Appoints Todd Shapiro As New Board Of Director And Hosts Investor Update

Posted by AGORACOM-JC at 8:57 AM on Monday, May 4th, 2020
  • Todd Shapiro has joined the board of director
  • Senior management will be hosting an investor update webinar on Tuesday, May 5, 2020, at 1:00 p.m. ET
  • To discuss the company’s fiscal year 2019 results, current developments on the agreement securing the rights to import COVID-19 test kits from South Korea, and the Artificial Intelligence side of the operations

TORONTO, May 04, 2020 – Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce Todd Shapiro has joined the board of director. After being a top rated Radio Show host & a brilliant marketing Entrepreneur with over 20 years of experience, he has recently moved on from main stream media to concentrate his efforts on being the CEO of Red Light Holland. Todd currently sits on the Board of Directors for Red Light Holland, JamStacked and Mogul Productions.

Janeen Stodulski stepped down from the board to make a seat available for Todd to join the Board. The Company thanks Janeen for all her efforts and leadership in the board, which helped streamlining and optimizing our operations. The Company wishes Janeen all the best in her future endeavours.

The Company also announces that senior management will be hosting an investor update webinar on Tuesday, May 5, 2020, at 1:00 p.m. ET to discuss the company’s fiscal year 2019 results, current developments on the agreement securing the rights to import COVID-19 test kits from South Korea, and the Artificial Intelligence side of the operations.

Investor Update Webinar Details:

Date: Tuesday, May 5, 2020
Time: 1:00 p.m. ET
RegistrationLink: https://us02web.zoom.us/webinar/register/WN_cOWa6oBCT3WAd7cL4CGKLg

Datametrex plans to answer questions previously sent to [email protected] and during the webinar – at management’s discretion and subject to time constraints. An archived video will be made available on the website.

About Datametrex

Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com).

For further information, please contact:

Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Jeff Stevens – Advisor
Phone: (647) 400-8494
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Tags: , , , , ,
Posted in Datametrex AI Limited | Comments Off on Datametrex $DM.ca Appoints Todd Shapiro As New Board Of Director And Hosts Investor Update

Falling for China’s Fake #Covid19 News Was Dangerous and Preventable – SPONSOR: Datametrex AI Limited $DM.ca

Posted by AGORACOM-JC at 9:15 PM on Sunday, May 3rd, 2020

SPONSOR: Datametrex AI Limited (TSX-V: DM) A revenue generating small cap A.I. company that NATO and Canadian Defence are using to fight fake news & social media threats. The company is working with US Government agencies on Covid19 and Coronavirus fake news and disinformation. The company also obtained the rights to import and sell COVID-19 test kits from South Korea – Click here for more info.

Falling for China’s Fake Covid-19 News Was Dangerous and Preventable

  • The Chinese government’s consistent record of censorship and manipulation of information during public health crises is in the public domain
  • It’s well documented
  • We would do well to look beyond the official Chinese numbers, rely on the information we can trust, and focus on what’s most important: containing and eradicating the deadly global pandemic.

By: Yaqiu Wang

As Covid-19 continues to cut a grim path across the globe, debates continue to rage about who is to blame. In one of his many moves to shift accountability for his own inept response to the crisis, US president Donald Trump said he would place a hold on funding for the World Health Organization, alleging that the agency “willingly took China’s assurances to face value” and “pushed China’s misinformation.”

But the truth is that everyone—the US government, the WHO, journalists, public health officials, and others—should have known better than to trust Beijing’s claims, whether in its initial dismissal of the possibility of human-to-human transmission, or in its current reports of infection and death-toll numbers. In China’s one-party authoritarian system, officials suppressing information and manipulating data for propaganda or career advancement is nothing new, and likely won’t change any time soon.

The Chinese government’s consistent record of censorship and manipulation of information during public health crises is in the public domain. It’s well documented. We would do well to look beyond the official Chinese numbers, rely on the information we can trust, and focus on what’s most important: containing and eradicating the deadly global pandemic.

Cover-ups, apathy, and inertia

Over the past two decades, Human Rights Watch has extensively documented the Chinese government’s censorship and falsification of information during public health crises. A government worker in southern China told me that she had little confidence in the accuracy of the non-contact digital thermometers she and her colleagues were instructed to use to check local residents’ temperature at checkpoints. “We don’t think they actually work. It was just for show, in case the [national authorities] come to inspect,” she said.

In the 2000s, numerous mass lead poisoning incidents were reported as China was quickly becoming known as “the world’s factory.” In a 2011 report, Human Rights Watch documented that government officials in provinces with high rates of industrial pollution restricted access to lead testing, deliberately withheld or falsified test results, and denied children treatment. Family members and journalists seeking information about the problem were intimidated and harassed.

During the Severe Acute Respiratory Syndrome (SARS) outbreak in 2003, authorities initially underreported infection rates and falsely proclaimed that the “atypical pneumonia” had “already been brought under effective control.” The cover-up contributed significantly to the spread of the disease. Contrary to current WHO praise for the Chinese government’s Covid-19 response, WHO officials at the time repeatedly expressed concern about underreporting and the lack of transparency.

In a 2005 report, Human Rights Watch detailed Chinese authorities’ harassment of AIDS activists and suppression of information that showed that China’s AIDS epidemic was largely caused by government-sponsored unsanitary blood-for-money programs.  In 2004, authorities in Henan, the province hardest hit at the time, said there were 25,036 carriers of HIV in the province, but local doctors and activists, based on their field research in affected villages, estimated that at least one million people had contracted HIV as a result of blood-selling schemes.

In the summer of 2008, for more than a month the Chinese government prohibited the domestic media from reporting on infants being poisoned by toxin-laced milk powder formula—which resulted in at least six deaths and sickened approximately 300,000 children. Ultimately, economic concerns prompted Chinese authorities to let up on media restrictions. Zhao Lianhai, the father of a poisoned-milk victim, was later sentenced to a two-and-a-half-year prison term for exposing the government’s failure to assist child victims.

In 2018, authorities across the country harassed, detained, and persecuted journalists, activists, lawyers, and families of victims for exposing China’s persistent faulty vaccine problems. News articles and social media posts that criticized the government’s failure to regulate the vaccine market properly were routinely censored.

The value of good information

To be sure, ensuring accurate information on the number of people infected with Covid-19 and the number of deaths is not easy, and some governments are admitting this is a challenge that makes containing the global pandemic all the more difficult. But in China, investigations by scientists, journalists, and citizens continue to be suppressed, just as they have been for decades.

The apathy and inertia pervasive within China’s vast bureaucracy hampers both accurate reporting and adequate detection of Covid-19 cases. The country’s history of cover-ups should have served as a warning to anyone reading the news that official Chinese information about the virus simply isn’t reliable.

As the saying goes, fool me once, shame on you; fool me twice, shame on me. No one should be fooled by information put out by the Chinese government the next time around.

Source: https://www.hrw.org/news/2020/04/30/falling-chinas-fake-covid-19-news-was-dangerous-and-preventable

Tags: , , , , ,
Posted in All Recent Posts | Comments Off on Falling for China’s Fake #Covid19 News Was Dangerous and Preventable – SPONSOR: Datametrex AI Limited $DM.ca

Israel Researchers Launch Clinical Trials To Test #CBD As #COVID19 Treatment Supplement – SPONSOR: Hollister Biosciences $HOLL.ca $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 9:00 PM on Sunday, May 3rd, 2020

SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated cannabis company with products in 220 California dispensaries and joint ventures, licensing agreement & partnerships with global brands. The company recently closed $20 MILLION deal with Venom Extracts adding $CDN 16.4 million in revenue and $CDN 2.48 million in EBITDA. Learn More

Israel Researchers Launch Clinical Trials To Test CBD As COVID-19 Treatment Supplement

Israeli researchers have launched three clinical trials that utilize CBD’s anti-inflammatory properties as potential COVID-19 treatment.

  • Israeli scientists have launched clinical trials into whether cannabis can play an effective role in stopping or slowing the coronavirus
  • Though lung health experts have warned smoking marijuana could exacerbate COVID-19 and its spread, Israeli scientists will study cannabidiol (CBD) alongside existing treatment options as a possible solution

By: The Fresh Toast , Benzinga Contributor

Israeli scientists have launched clinical trials into whether cannabis can play an effective role in stopping or slowing the coronavirus. Though lung health experts have warned smoking marijuana could exacerbate COVID-19 and its spread, Israeli scientists will study cannabidiol (CBD) alongside existing treatment options as a possible solution.

Last week, InnoCan Pharma announced a collaboration with Tel Aviv University to instill CBD medicine through exosomes — or the small cell structures created when stem cells multiply. The unconventional method will utilize the exosomes as “homing missiles,” as they can uniquely target cell organs damaged by COVID-19. Researchers then believe CBD’s anti-inflammatory properties will repair the damaged cells through a synergistic effect. As COVID-19 attacks the respiratory system, scientists will have patients receive CBD-enriched exosomes through an inhalation device. Previous studies have shown CBD can help regulate the body’s immune system and reduce inflammation throughout the body.

A second clinical trial will occur over the coming weeks and includes 10 Covid-19 patients currently undergoing treatment in Israel’s Rabin Medical Center. Doctors will combine traditional steroids and CBD, with the belief CBD will enhance the therapeutic potential of the steroids. The trial, conducted by Stero Biotechs in collaboration with Mor Research Application, already has plans to expand treatment to 40 additional patients should it prove successful.

“We estimate that our CBD-based treatment can enhance the current treatment of those patients who are in life-threatening conditions,” Stero Biotechs founder and CEO David Bassa said in a statement. “Hospitalized COVID-19 patients are mostly being treated with steroids and our study is planned to demonstrate the benefit of a combined solution with Steroid treatments. We are hopeful that this study will lead to faster benefit for the growing number of COVID-19 patients in Israel and around the world.”

A third study, launched by Tel Aviv’s Ichilov Medical Center, will investigate whether CBD’s anti-inflammatory properties could lower respiratory symptoms experienced in moderate COVID-19 patients.

Canadian researchers have also announced intentions to study what role cannabis can play in slowing COVID-19. They also believe marijuana’s anti-inflammatory properties could provide a crucial role in potential treatment.

Source: https://www.benzinga.com/markets/cannabis/20/04/15877325/israel-researchers-launch-clinical-trials-to-test-cbd-as-covid-19-treatment-supplement

Tags: , , , , , ,
Posted in Hollister Biosciences | Comments Off on Israel Researchers Launch Clinical Trials To Test #CBD As #COVID19 Treatment Supplement – SPONSOR: Hollister Biosciences $HOLL.ca $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Bot or not? #AI looks at #Twitter behavior to sort real accounts from fake – SPONSOR: Datametrex AI Limited $DM.ca

Posted by AGORACOM-JC at 5:20 PM on Thursday, April 30th, 2020

SPONSOR: Datametrex AI Limited (TSX-V: DM) A revenue generating small cap A.I. company that NATO and Canadian Defence are using to fight fake news & social media threats. The company is working with US Government agencies on Covid19 and Coronavirus fake news and disinformation. The company also obtained the rights to import and sell COVID-19 test kits from South Korea – Click here for more info.

Bot or not? A.I. looks at Twitter behavior to sort real accounts from fake

  • For the past several years, there’s been heightened concern about the impact of so-called bots on platforms like Twitter
  • A bot in this context is a fake account synonymous with helping to spread fake news or misinformation online

By: Brinkwire

For the past several years, there’s been heightened concern about the impact of so-called bots on platforms like Twitter. A bot in this context is a fake account synonymous with helping to spread fake news or misinformation online. But how exactly do you tell the difference between an actual human user and a bot? While clues such as the use of the basic default “egg” avatar, a username consisting of long strings of numbers, and a penchant for tweeting about certain topics might provide a few pointers, that’s hardly conclusive evidence.

That’s the challenge a recent project from a pair of researchers at the University of Southern California and University of London set out to solve. They have created an A.I. that’s designed to sort fake Twitter accounts from the real deal, based on their patterns of online behavior.

“Detecting bots can be very challenging as they continuously evolve and become more sophisticated,” Emilio Ferrara, research assistant professor in the USC Department of Computer Science, told Digital Trends. “Existing tools that work well with older and simpler types of bots are not as accurate to predict more complex ones. So it’s always exciting to identify new, previously unknown characteristics of the behavior of human users that are not yet exhibited by bots. This could [be used to help] improve the accuracy of detection tools.”

The researchers leveraged various datasets of hand-labeled examples of both fake and real Twitter account messages, produced by other researchers in the community. In total, they trained their system on 8.4 million tweets from 3,500 human accounts and an additional 3.4 million tweets from 5,000 bots. This helped them to uncover a variety of insights into tweeting patterns. For instance, human users are up to five times more likely to reply to messages. They also get increasingly interactive with other users over the course of a long Twitter session, while the length of an average tweet decreases during this same time frame. Bots, on the other hand, show no such changes.

But don’t expect this work to be the definitive lasting word in this field. Just like the cat-and-mouse game between software companies and hackers, whereby one group tries to close vulnerabilities and the other works to find new ones, the field of bot discovery will continue to develop.

“These findings will inform future bot detection tools,” Ferrara said. “However, we expect that bot-making tools will see these findings as well, so it will be interesting to see when — or how soon — some of the open-source bot-making tools that are available online will adjust to reflect the human behavioral trends that we discovered.”

A paper describing the work was recently published in the journal Frontiers in Physics.

Source: https://en.brinkwire.com/news/bot-or-not-a-i-looks-at-twitter-behavior-to-sort-real-accounts-from-fake/

Tags: , , , , ,
Posted in Datametrex AI Limited | Comments Off on Bot or not? #AI looks at #Twitter behavior to sort real accounts from fake – SPONSOR: Datametrex AI Limited $DM.ca

Empower Clinics $CBDT.ca Confirms Phase One and Phase Two Corona Virus #COVID19 Antibody Testing is Underway and Provides Updates on Timing of Fourth Quarter and Annual Financial Results $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 3:55 PM on Thursday, April 30th, 2020
  • Empower confirms it has commenced COVID-19 antibody testing in clinics under the phase one and phase two rollout plans,
  • Received first Rapid COVID-19 test kits and places additional purchases of Rapid COVID-19 test kits

VANCOUVER, BC / April 29, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated life sciences company, is pleased to announce it is actively testing patients using COVID-19 antibody testing under its phase one and phase two rollout plans in its Sun Valley Health clinics in Phoenix, AZ. The Company has also received its first Rapid COVID-19 antibody test kits and has purchased additional Rapid test kits to start meeting testing demand. The Company also provides an update on the timing of the release of its financial results and associated filings for the fourth quarter and fiscal year ended December 31, 2019.

The Company is utilizing the temporary relief exemption provided by the Ontario Securities Commission under Ontario Instrument 51-502 – Temporary Exemption from Certain Corporate Finance Requirements (the “Instrument“), which provides a 45-day extension for periodic filings, including annual audited financial statements, as required by section 4.1(2) of National Instrument 51-102 – Continuous Disclosure Obligations, and related management’s discussion and analysis and CEO and CFO certifications (collectively, the “Annual Filings“), for the year ended December 31, 2019.

In accordance with the Instrument, the Company intends to file its Annual Filings no later than the extended deadline, as permitted under the Instrument, of June 15, 2020.

Until the Company has filed the Annual Filings, the Company confirms that its management and other insiders are subject to a trading blackout that reflects the principles in section 9 of National Policy 11-207 Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions. The Company further confirms that, other than as disclosed in this news release or other news releases or material change reports filed by the Company since November 14, 2019, being the date of filing of the Company’s unaudited interim financial statements and related filings for the period ended September 30, 2019, there have been no undisclosed material business developments with respect to the Company.

“The Company’s four-phase national COVID-19 testing program utilizing Rapid COVID-19 test kits is underway in the United States and our first patients are expecting test results starting today,” said Steven McAuley, Chairman & CEO of Empower. “The operational processes we have established to manage the patient experience are proving stable and effective, as is the technology workflow that registers a patient, books an appointment and collects payment on the Sun Valley Health website.”

Phase One – Testing in clinics in Arizona, utilizing a patient blood draw by clinic phlebotomists, then samples are sent to our laboratory test partner for analysis, with test results expected within 48 hours. This program is now active and appointment rates are expanding rapidly.

Phase Two – Offering a Rapid COVID-19 antibody test with results in 1-15 minutes. The service will be offered in-clinics using a drive-up service, conducted by Company clinic staff. In addition, an outbound door-step service, to support a variety of consumer, patient and community needs will be offered using certified mobile technicians. The online portal will be open to book appointments commencing May 1, 2020.

Phase Three – Business Employee Testing (BET) programs, offering Rapid COVID-19 testing to businesses on a one-time basis, repeat basis and/or subscription basis, to assist businesses to get back to work safely, will be offered. The Company anticipates phase three services will commence in May 2020.

Phase Four – U.S. nationwide roll-out, offering all phases of Company services, that can be accessed online at Company websites and call centers, to purchase Rapid COVID-19 test kits. The Company anticipates phase four services to commence in Q3 2020.

ABOUT EMPOWER

Empower is a vertically integrated health & wellness brand with a network of corporate and franchised health & wellness clinics in the U.S. The Company is building its first hemp-derived CBD extraction facility and produces its proprietary line of cannabidiol (CBD) based products. The Company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company now offers COVID-19 testing options in the United States and physician-based consultations, to address COVID-19 concerns.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley
CEO
[email protected]
604-789-2146

Investors: Dustin Klein
SVP, Business Development
720-352-1398
[email protected]

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s expected timing of filing of its Annual Filings, the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four as noted above, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Tags: , , , , ,
Posted in All Recent Posts, Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca Confirms Phase One and Phase Two Corona Virus #COVID19 Antibody Testing is Underway and Provides Updates on Timing of Fourth Quarter and Annual Financial Results $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Hollister Biosciences $HOLL.ca Closes Acquisition of AlphaMind Brands Inc. $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:15 AM on Thursday, April 30th, 2020
  • Company has now closed its acquisition of AlphaMind Brands Inc., a growth stage company, that is developing a portfolio of certified legal mushroom based natural health products
  • Hollister will not be assuming any long-term debt; no new control position will be created and there is no change in management or the Board of Directors of Hollister in connection with the Transaction

VANCOUVER, April 30, 2020 - Hollister Biosciences Inc. (CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“) – a diversified cannabis branding company with products in over 220 dispensaries throughout California, is pleased to announce that further to the signing of the definitive agreement, as amended (the “SEA“), the Company has now closed its acquisition of AlphaMind Brands Inc. (“AlphaMind“), a growth stage company, that is developing a portfolio of certified legal mushroom based natural health products (the “Transaction“).

“We are very pleased to close our acquisition of AlphaMind”, shared Carl Saling, Founder and CEO of Hollister.  “It is our continual objective to broaden our product scope and Alphamind, with its experienced management team, is a perfect foothold for us in the fast-growing market for medicinal mushrooms and complements our existing cannabis and hemp-based product offering.  We are excited to bring another promising brand under the Hollister umbrella, especially in such a fast growing and exciting sector.”

“We are very pleased to have closed this transaction”, shared Dr. Nikos C. Apostolopoulos, Chief Product & Research Officer of Alphamind Brands.  “We are looking forward to working with Hollister to build out our medicinal mushroom based product line and conducting further R&D to develop an exciting IP portfolio surrounding psilocybin based pharmaceutical treatments.”

Key Terms of The Transaction

Pursuant to the terms of the SEA, the Company has acquired AlphaMind for consideration of CDN$1,200,000 which is being satisfied by the issuance of 4,200,000 Hollister common shares (the “Payment Shares“) on the Closing Date pro rata to the shareholders of AlphaMind and an additional 1,800,000 common shares (the “Earn-Out Shares“) to be issued pro rata to the former shareholders of AlphaMind on the earlier of (i) AlphaMind meeting certain milestones (detailed below) or (ii) December 31st, 2021.

  • The Payment Shares and the Earn-Out Shares will be issued at a deemed value of $0.20 per share;
  • The Payment Shares are subject to certain voluntary hold periods as follows: 331/3% until May 30th, 2020; an additional 331/3% until June 30th, 2020; and the remaining 331/3% until August 30th, 2020;
  • The Earn-Out Shares will be issued on the earlier of (i) December 31st, 2020, or (ii) upon AlphaMind’s first production run or its first sales of product.

Hollister will not be assuming any long-term debt; no new control position will be created and there is no change in management or the Board of Directors of Hollister in connection with the Transaction.

About AlphaMind Brands Inc.

Alphamind Brands is a Canada and US based growth stage company, that is developing a portfolio of certified legal mushroom based natural health products. It is also actively conducting R&D initiatives, led by Dr. Nikos C. Apostolopoulos, who is exploring psilocybin based pharmaceutical treatments.  The company’s “ready to ship” product SKU’s include Cordyceps, Lion’s Mane, Shiitake, Oyster and Reishi Mushroom based: liquid tinctures, concentrated mushroom powder(s), teas, and chocolate. 

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

ON BEHALF OF THE BOARD

“Carl Saling”

CEO and Director

The CSE does not accept responsibility for the adequacy or accuracy of this release.

The CSE has not in any way passed upon the merits of the Transaction and has neither approved nor disapproved the contents of this press release.

The securities to be issued in connection with the Transaction have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “1933 Act“), or under any state securities laws, and may not be offered or sold, directly or indirectly, or delivered within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the 1933 Act) absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or a solicitation to buy such securities in the United States.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

View original content to download multimedia:http://www.prnewswire.com/news-releases/hollister-biosciences-closes-acquisition-of-alphamind-brands-inc-301049911.html

Tags: , , , , , ,
Posted in Hollister Biosciences | Comments Off on Hollister Biosciences $HOLL.ca Closes Acquisition of AlphaMind Brands Inc. $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Toddler Meal Ideas for Picky Eaters – SPONSOR: Else Nutrition $BABY.ca $MAT $KMB $BMY $ABT $WYE

Posted by AGORACOM-JC at 5:07 PM on Wednesday, April 29th, 2020

SPONSOR: Else Nutrition Holdings Inc. (TSX-V: BABY)The award winning, plant-based nutrition company for small cap investors. The company has a $10,000,000 cash balance for US product launch In Q2 2020 with International agreements in Q3. Learn More

Toddler Meal Ideas for Picky Eaters

By Nicole Silber, RD, CSP, CLC

Children undergo more changes to their growth, development and eating patterns in the years between birth and preschool than any other time in their lives. When babies turn into toddlers, their relatively consistent, predictable eating becomes very inconsistent, paving the way for what many parents would describe as picky eating.

Many parents are concerned with how their toddlers eat (and don’t eat for that matter). What we do know from the Feeding Infants and Toddlers Study (FITS) is that many toddlers and preschoolers eat too much sodium and saturated fat, and not enough key nutrients like potassium, Vitamin D and fiber. But, some of the concerns that I hear from parents regarding their toddlers’ eating stem from a gap in knowing just how much healthy toddlers actually need, and what are normal versus problematic eating behaviors. These concerns usually lead to mealtime tensions, which can perpetuate the picky eating cycle.

Understanding the Needs for Toddler Meals

Understanding what is normal can be very helpful for parents.  Expect toddler meals to be consistently inconsistent – meaning they may skip occasional meals (yes, that means eat a few bites, or nothing), show fluctuating appetites daily based on changing growth needs (meaning when they’re going through a growth spurt they eat much more), and refuse foods one day that they gobbled up the day before. Their willingness to eat at meals may be affected by too much snacking (or grazing), fear of new foods that suddenly develop, or any minor discomfort from teething, a cold or even constipation can impact their willingness to put certain foods, textures and flavors into their mouths. And as a reminder, toddlers are much smaller than adults, so they do not need adult-like portions. For example, healthy toddlers need just 1 cup of veggies each day, so if that’s broken up into 2 meals and a snack that can be just 1/3 of a cup per sitting.  One day they may eat double that, and the next eat none, so look at the average.

Managing expectations can help relieve some parental stress and make way for more positive mealtime environments.  Pushing too hard, trying to convince, sneaking foods, accommodating requests (going to the kitchen and making 3 different dinners), offering bribes to finish the broccoli (yes, we’ve all been there) are all tempting, but can create power struggles that actually intensify the feeding refusals. But, there are some productive things that parents can do to encourage more variety with picky eaters, and the American Academy of Pediatrics (AAP) offers some great tips, like including children in cooking, encouraging family meals, and offering foods repeatedly and in flavorful ways.

Supplementing Toddler Meal Ideas With Something Else

While it’s developmentally normal for toddlers to go through some picky eating phases, some children, and parents alike, struggle to eat balanced, varied meals. And, for children who have any major diet restrictions because of allergies, medical or other lifestyle reasons, they are at higher risk for nutritional deficiencies during times of picky eating. That is when a fortified toddler nutrition drink, like Else, can be a great supplement to their diets. Else complete plant-based toddler meals can help in 2 ways: A more direct benefit is that Else provides these children with an extra boost of calories, fat (particularly unsaturated fat), protein, fiber, omega 3s and many key vitamins and minerals, like iron, potassium, vitamin D needed to support this time of rapid growth. And, Else can provide parents with the reassurance that their little ones are getting the nutrients they need. This reassurance can minimize the stress and pressure placed by parents and felt by kids at mealtimes, which can ultimately encourage more relaxed, varied eating.

Source: https://elsenutrition.com/blogs/news/easy-toddler-meal-ideas-for-picky-eaters

Tags: , , , , ,
Posted in All Recent Posts, Else Nutrition Holdings Inc. | Comments Off on Toddler Meal Ideas for Picky Eaters – SPONSOR: Else Nutrition $BABY.ca $MAT $KMB $BMY $ABT $WYE

Discovering the Benefits of CBD Oil SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 2:25 PM on Wednesday, April 29th, 2020

SPONSOR: Mota is seeking to become a vertically integrated global CBD brand. Mota is creating sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota. Combined total sales of almost $29,000,000 with a EBITDA of approximately 12.5% (2019) . Click Here for More Info

Mota large

CBD oil is increasingly acclaimed for its benefits. Use as an e-liquid for vaping, but also as a dietary supplement to fight against stress or depression, CBD is everywhere.

Find out what its benefits are, how to consume it, and where to find it.

With some of the best online suppliers in Europe, British users can now easily find and order CBD flowers in UK. It has simplified the way to purchase high-quality CBD online, and we can now enjoy the best CBD oils.

What is CBD oil?

CBD, or cannabidiol, is part of the family of cannabinoids, a group of molecules found in the hemp plant, such as THC or CBD. We all have so-called cannabinoid receptors in our brains, which explains why these compounds have a more or less significant impact on the human nervous system.

CBD oil is extracted from the cannabis plant. It contains mostly cannabidiol, the concentration of which varies depending on the product. Today it is mainly used as an e-liquid for electronic cigarettes, as CBD oil to add in food and drinks, and CBD capsules.

While the hemp plant has been cultivated for over 6.000 years in China, it is only today that CBD oil is becoming more and more popular, as scientists discover many benefits for our organism. Indeed, unlike THC, another cannabinoid, CBD does not have psychotropic properties. For this reason, cannabidiol is also called “therapeutic cannabis”!

What are the effects of CBD oil?

Unlike THC, the effects of CBD oil are not harmful to our nervous system. CBD does not cause a feeling of intoxication or euphoria, unlike THC, and therefore no loss of control.

Conversely, it offers a feeling of serenity and a sense of relaxation. CBD is also found in recognized drugs like Cannador, Sativex, or Epidiolex.

To start with, CBD oil can help you fall asleep. If it does not have the effect of a sleeping pill, it will, however, cause your body to relax to promote falling asleep indirectly.

Likewise, CBD oil can help you not only to combat stress but also to regulate your mood. Indeed, CBD acts in particular on receptors linked to anxiety. For this reason, it is reputed to be a powerful anxiolytic and is effective in treating depression.

Note that paradoxically, CBD oil can help you fight against drug addiction since it will promote emotional balance while helping you overcome anxiety and stress, often overwhelming during withdrawal.

Finally, CBD oil can be used as an anti-inflammatory, especially in the case of Crohn’s disease, a chronic inflammatory disease of the digestive system.

How should you use CBD oil?

CBD oil is consumed orally, by placing 1 to 2 drops on your tongue or by adding them to your food or drink. The bottles sold are therefore often equipped with a pipette. After swallowing the CBD oil drops, leave it on for 30 seconds before continuing to eat or keep busy.

Please note, it is essential not to exceed 3 doses per day. If you take too much CBD oil, you risk increasing the relaxing effects and wanting to sleep! The ideal is to start with a low dosage and increase it gradually if you support it.

Also, CBD oil is not recommended for pregnant women.

Is CBD oil legal in the UK?

Cannabis derivatives do not have an outstanding reputation, in particular, because of THC, the compound which has psychotropic effects. European legislation is therefore relatively strict with cannabidiol. For example, any product containing THC is prohibited if the THC level exceeds 0.2 %.

However, products from Cannabis sativa seeds and stems are not prohibited in the UK, which explains why most of the CBD oils currently on sale come from them. Despite everything, CBD oil remains banned for minors. No law has been enacted regarding CBD oil, but case law prevails until European law issues an opinion on the subject, not always in a pleasant manner!

Where to buy CBD oil?

CBD-based products are very numerous: crystals (the purest form) for culinary preparations or other uses of this type, oil, e-liquid for electronic cigarettes, CBD flowers, CBD resins, etc. You will, therefore, have no harm to find CBD for your consumption.

On the Internet, you will mainly find CBD oil, as on the online store. You will find a whole lot of websites that are claiming to sell the best CBD products. However, you should only buy the best quality of CBD flowers and CBD oils.

Check websites such as Justbob.shop to find the right CBD products. As a leading company in Europe, this supplier from Italy is offering natural CBD flowers and great CBD oils. Also, they are following a set of many quality controls, and they are recognized by the Italian authorities, which means that they are well-known and that they are complying with local and European laws.

Source: London Loves Business

https://londonlovesbusiness.com/discovering-the-benefits-of-cbd-oil/

Tags: , , , , , , , , , ,
Posted in All Recent Posts, Mota Ventures Corp. | Comments Off on Discovering the Benefits of CBD Oil SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

« Older Entries
Newer Entries »